Liminatus Pharma (LIMN) Competitors $3.41 +0.63 (+22.66%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock LIMN vs. BNTC, ALDX, AMRN, CAPR, CTMX, ALT, FDMT, TNXP, LRMR, and DMACShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include Benitec Biopharma (BNTC), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Capricor Therapeutics (CAPR), CytomX Therapeutics (CTMX), Altimmune (ALT), 4D Molecular Therapeutics (FDMT), Tonix Pharmaceuticals (TNXP), Larimar Therapeutics (LRMR), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors Benitec Biopharma Aldeyra Therapeutics Amarin Capricor Therapeutics CytomX Therapeutics Altimmune 4D Molecular Therapeutics Tonix Pharmaceuticals Larimar Therapeutics DiaMedica Therapeutics Liminatus Pharma (NASDAQ:LIMN) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Is LIMN or BNTC more profitable? Liminatus Pharma's return on equity of 0.00% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Liminatus PharmaN/A N/A N/A Benitec Biopharma N/A -38.26%-35.71% Which has higher earnings and valuation, LIMN or BNTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiminatus PharmaN/AN/AN/AN/AN/ABenitec BiopharmaN/AN/A-$21.75M-$1.51-8.60 Do insiders & institutionals have more ownership in LIMN or BNTC? 52.2% of Benitec Biopharma shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate LIMN or BNTC? Benitec Biopharma has a consensus price target of $26.00, indicating a potential upside of 100.15%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media refer more to LIMN or BNTC? In the previous week, Benitec Biopharma had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Liminatus Pharma. Benitec Biopharma's average media sentiment score of 0.64 beat Liminatus Pharma's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Liminatus Pharma Neutral Benitec Biopharma Positive SummaryBenitec Biopharma beats Liminatus Pharma on 8 of the 10 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$88.69M$213.68M$2.58B$9.73BDividend YieldN/AN/A2.55%4.09%P/E RatioN/AN/A22.0425.99Price / SalesN/AN/A78.25122.97Price / CashN/AN/A23.2358.38Price / BookN/AN/A31.696.38Net IncomeN/AN/A$31.01M$265.56M7 Day Performance-14.75%-3.58%0.81%1.89%1 Month Performance-41.00%-9.41%1.52%1.23%1 Year PerformanceN/A135.33%30.16%21.10% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$3.41+22.7%N/AN/A$88.69MN/A0.00N/AGap UpHigh Trading VolumeBNTCBenitec Biopharma1.4454 of 5 stars$12.88+2.5%$26.00+101.9%+41.7%$338.10M$80K-8.5320News CoverageALDXAldeyra Therapeutics2.0997 of 5 stars$5.63+0.5%$9.50+68.7%+9.7%$337.24MN/A-6.6210AMRNAmarin0.2717 of 5 stars$15.85+0.2%$12.00-24.3%+22.1%$328.21M$219.36M-4.32360CAPRCapricor Therapeutics3.0781 of 5 stars$7.17-6.5%$22.56+214.6%+53.1%$327.81M$22.27M-4.37101CTMXCytomX Therapeutics4.0795 of 5 stars$1.97-1.5%$5.75+191.9%+59.8%$324.87M$138.10M3.52170ALTAltimmune3.2732 of 5 stars$3.63+0.3%$17.40+379.3%-48.6%$320.37M$20K-3.0850Trending NewsFDMT4D Molecular Therapeutics2.1259 of 5 stars$6.85+4.3%$30.40+343.8%-54.9%$319.91M$33K-1.94120TNXPTonix Pharmaceuticals3.1734 of 5 stars$36.05-1.3%$70.00+94.2%-0.4%$316.16M$10.09M-0.9150LRMRLarimar Therapeutics2.2639 of 5 stars$3.77+3.3%$18.43+388.8%-54.7%$312.07MN/A-2.4230DMACDiaMedica Therapeutics1.5951 of 5 stars$6.00+4.0%$12.33+105.6%+60.3%$310.14MN/A-8.7020Short Interest ↑ Related Companies and Tools Related Companies Benitec Biopharma Competitors Aldeyra Therapeutics Competitors Amarin Competitors Capricor Therapeutics Competitors CytomX Therapeutics Competitors Altimmune Competitors 4D Molecular Therapeutics Competitors Tonix Pharmaceuticals Competitors Larimar Therapeutics Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access